Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis.

Johannes PöhlmannBeth D MitchellSanjay BajpaiBeatrice OsumiliWilliam J Valentine

Published in: Journal of diabetes science and technology (2019)

The usability advantage of NG over IG was projected to reduce SHE-related treatment costs in the US setting. NG has the potential to improve hypoglycemia emergency care and reduce SHE-related treatment costs.

Keyphrases

type diabetes
healthcare
emergency department
public health
palliative care
climate change
early onset
chronic pain
social media
insulin resistance
electronic health record
smoking cessation
replacement therapy
hyaluronic acid